Role of pharmacist during COVID-19 pandemic: A retrospective study focused on critically ill COVID-19 patients.
COVID-19
ICU patients
Interventions
Pharmacist
Journal
Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society
ISSN: 1319-0164
Titre abrégé: Saudi Pharm J
Pays: Saudi Arabia
ID NLM: 9705695
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
21
03
2021
accepted:
04
07
2021
pubmed:
27
7
2021
medline:
27
7
2021
entrez:
26
7
2021
Statut:
ppublish
Résumé
During the Coronavirus 2019 (COVID-19) crisis, there has been a huge demand for medications and unprecedented utilization of intensive care unit (ICU) services that subsequently and profoundly impacted the quality of medical care provided to COVID-19 patients. This study aimed to shed light on the role of pharmacists on the health care provided to critically ill COVID-19 patients. A retrospective study, was conducted in Diriyah hospital in Riyadh, Saudi Arabia on all COVID-19 patients admitted to the ICU between June 27th and August 15th, 2020 until patients were transferred to the medical ward, discharged, or deceased. All medication related interventions performed by pharmacists have been documented electronically, collected and subsequently categorized and analyzed. The mean age of patients was 58.8 years (±12.98 SD), with age of >64 years in approximately 37%. Four hundred and seventy interventions (470) were made by pharmacists of which 32%, 11.7%, 4%, 2.6%, 2.1% were due to error in dosing regimens, drug duplication, missing drug information, drugs requiring prior authorization, and missing critical information, respectively; while 40.6% were due to medication shortage of which 40.3% were substituted with alternative medications. Based on the analysis of drugs involved in interventions, medication groups that were mainly associated with interventions included antibiotics (16.8%), electrolytes/minerals (11.7%) and vitamins (9.4%). During health crises such as COVID-19 pandemic, the role of pharmacists in the ICU services becomes extremely crucial for providing better patients' outcomes. Further studies should be conducted to follow up these findings in the context of COVID-19 pandemic.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
During the Coronavirus 2019 (COVID-19) crisis, there has been a huge demand for medications and unprecedented utilization of intensive care unit (ICU) services that subsequently and profoundly impacted the quality of medical care provided to COVID-19 patients. This study aimed to shed light on the role of pharmacists on the health care provided to critically ill COVID-19 patients.
METHODS
METHODS
A retrospective study, was conducted in Diriyah hospital in Riyadh, Saudi Arabia on all COVID-19 patients admitted to the ICU between June 27th and August 15th, 2020 until patients were transferred to the medical ward, discharged, or deceased. All medication related interventions performed by pharmacists have been documented electronically, collected and subsequently categorized and analyzed.
RESULTS
RESULTS
The mean age of patients was 58.8 years (±12.98 SD), with age of >64 years in approximately 37%. Four hundred and seventy interventions (470) were made by pharmacists of which 32%, 11.7%, 4%, 2.6%, 2.1% were due to error in dosing regimens, drug duplication, missing drug information, drugs requiring prior authorization, and missing critical information, respectively; while 40.6% were due to medication shortage of which 40.3% were substituted with alternative medications. Based on the analysis of drugs involved in interventions, medication groups that were mainly associated with interventions included antibiotics (16.8%), electrolytes/minerals (11.7%) and vitamins (9.4%).
CONCLUSION
CONCLUSIONS
During health crises such as COVID-19 pandemic, the role of pharmacists in the ICU services becomes extremely crucial for providing better patients' outcomes. Further studies should be conducted to follow up these findings in the context of COVID-19 pandemic.
Identifiants
pubmed: 34305425
doi: 10.1016/j.jsps.2021.07.010
pii: S1319-0164(21)00137-7
pmc: PMC8282452
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1050-1055Informations de copyright
© 2021 The Author(s).
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
BMJ. 2016 May 03;353:i2139
pubmed: 27143499
Int J Clin Pharm. 2020 Apr;42(2):305-308
pubmed: 32240484
Infect Dis Model. 2020 Feb 11;5:248-255
pubmed: 32099934
J Qual Clin Pract. 2001 Dec;21(4):99-103
pubmed: 11856403
Anticancer Res. 2015 Jan;35(1):457-60
pubmed: 25550587
Br J Clin Pharmacol. 2004 Apr;57(4):513-21
pubmed: 15025751
Intensive Care Med. 2003 May;29(5):691-8
pubmed: 12665997
Crit Care. 2010;14(5):R174
pubmed: 20920322
Medicine (Baltimore). 2018 Mar;97(9):e9865
pubmed: 29489684
Ann Med Surg (Lond). 2020 Nov 12;60:445-450
pubmed: 33251004
Saudi Med J. 2008 Feb;29(2):277-81
pubmed: 18246241
Risk Manag Healthc Policy. 2020 May 06;13:373-378
pubmed: 32547271
Lancet. 1998 Feb 28;351(9103):643-4
pubmed: 9500322
Am J Health Syst Pharm. 2001 Oct 1;58(19):1835-41
pubmed: 11596700
Int J Clin Pharm. 2018 Apr;40(2):360-367
pubmed: 29380236
Am J Health Syst Pharm. 2020 Jul 7;77(14):1097-1099
pubmed: 32435815
Stud Health Technol Inform. 2017;234:13-17
pubmed: 28186008
Crit Care Explor. 2021 Jan 08;3(1):e0323
pubmed: 33458690
Saudi Pharm J. 2013 Oct;21(4):371-4
pubmed: 24227956
Am J Health Syst Pharm. 2020 Jul 7;77(14):1096-1097
pubmed: 32399549
J Am Pharm Assoc (Wash). 2001 Mar-Apr;41(2):192-9
pubmed: 11297331
Res Social Adm Pharm. 2021 Jan;17(1):1853-1858
pubmed: 33317764
Ann Intensive Care. 2021 Feb 18;11(1):36
pubmed: 33604873
Crit Care Med. 1997 Aug;25(8):1289-97
pubmed: 9267940
Chest. 2013 Nov;144(5):1687-1695
pubmed: 24189862
Crit Care Med. 2019 Sep;47(9):1276-1278
pubmed: 31415315
Am J Health Syst Pharm. 2020 Nov 16;77(23):1986-1993
pubmed: 32417878
JAMA. 2020 Apr 28;323(16):1610-1612
pubmed: 32129805
Ther Clin Risk Manag. 2014 Aug 07;10:631-9
pubmed: 25120369
J Oncol Pharm Pract. 2021 Mar;27(2):305-311
pubmed: 32326873
J Oncol Pharm Pract. 2021 Jun;27(4):897-901
pubmed: 32703083
Crit Care. 2008;12(2):208
pubmed: 18373883
Crit Care Med. 1994 Jun;22(6):1044-8
pubmed: 8205814